Novavax Covid vaccine found 90% effective against Covid-19 variants

New Delhi: On Monday, Novavax announced that its Covid vaccine — NVX-CoV2373 —demonstrated 100% protection against moderate and severe disease with 90.4% efficacy overall in the phase-3 trial. Novavax said in a press statement on June 14, ‘NVX-CoV2373, recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.’

As per Novavax, the study employed 29,960 participants across 119 sites in the U.S. and Mexico to assess efficacy, safety and immunogenicity, with importance on recruiting a representative population of communities and demographic groups most affected by the disease.

According to Stanley C. Erck, Novavax CEO and President, Novavax was one step closer to approaching the critical and persistent global public health need for additional COVID-19 vaccines. ‘These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection,’ he said.

The company announced that it ‘intends to file for regulatory authorizations in the third quarter, upon completion of the final phases of process qualification and assay validation needed to meet chemistry, manufacturing and controls (CMC) requirements. Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021.’

Gregory M. Glenn, M.D., President of Research and Development, Novavax said, “PREVENT-19 confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile. These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. Our vaccine will be a critical part of the solution to COVID-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the U.S. Government.’